These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22496260)

  • 21. The debut of dueling viewpoints.
    Bauchner H; Fontanarosa PB
    JAMA; 2012 Apr; 307(14):1532. PubMed ID: 22496269
    [No Abstract]   [Full Text] [Related]  

  • 22. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    Ioannidis JPA
    JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical trials and tribulations. Cholesterol veers off script.
    Couzin J
    Science; 2008 Oct; 322(5899):220-3. PubMed ID: 18845747
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiac risk factors: new cholesterol and blood pressure management guidelines.
    Anthony D; George P; Eaton CB
    FP Essent; 2014 Jun; 421():28-43. PubMed ID: 24936717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of low-density lipoprotein cholesterol in assessment and management of cardiovascular disease risk.
    Jialal I; Remaley AT
    Clin Pharmacol Ther; 2014 Jul; 96(1):20-2. PubMed ID: 24942398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New statin introduction. With more power against hypercholesterolemia].
    MMW Fortschr Med; 2002 Dec; 144(50):64. PubMed ID: 14610873
    [No Abstract]   [Full Text] [Related]  

  • 27. New guidelines in statin therapy.
    Dinman S
    Plast Surg Nurs; 2005; 25(2):109-10. PubMed ID: 15983503
    [No Abstract]   [Full Text] [Related]  

  • 28. A paradigm shift in the treatment of atherosclerosis.
    Ferrières J
    Arch Cardiovasc Dis; 2015; 108(6-7):337-9. PubMed ID: 26148633
    [No Abstract]   [Full Text] [Related]  

  • 29. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
    Capriotti T
    Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
    [No Abstract]   [Full Text] [Related]  

  • 30. The safety of statins in children.
    Lamaida N; Capuano E; Pinto L; Capuano E; Capuano R; Capuano V
    Acta Paediatr; 2013 Sep; 102(9):857-62. PubMed ID: 23631461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lipid lowering by rosuvastatin: how do statins differ?].
    Laufs U
    Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669
    [No Abstract]   [Full Text] [Related]  

  • 32. Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
    Kerst LL; Mauro VF
    Ann Pharmacother; 2004 Jun; 38(6):1060-4. PubMed ID: 15121997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Stone NJ; Robinson JG; Lichtenstein AH; Bairey Merz CN; Blum CB; Eckel RH; Goldberg AC; Gordon D; Levy D; Lloyd-Jones DM; McBride P; Schwartz JS; Shero ST; Smith SC; Watson K; Wilson PW;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt B):2889-934. PubMed ID: 24239923
    [No Abstract]   [Full Text] [Related]  

  • 34. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
    Stone NJ; Bilek S; Rosenbaum S
    Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid-lowering medications: what the new guidelines and data mean to women.
    Schwartz JB
    J Gend Specif Med; 2001; 4(2):9-13. PubMed ID: 11480105
    [No Abstract]   [Full Text] [Related]  

  • 37. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy.
    Jafri H; Alsheikh-Ali AA; Karas RH
    J Am Coll Cardiol; 2010 Jun; 55(25):2846-54. PubMed ID: 20579542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
    Robinson JG
    Future Cardiol; 2014 Mar; 10(2):149-52. PubMed ID: 24762237
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanisms of disease: HDL metabolism as a target for novel therapies.
    Rader DJ
    Nat Clin Pract Cardiovasc Med; 2007 Feb; 4(2):102-9. PubMed ID: 17245404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.